168 related articles for article (PubMed ID: 26539494)
21. The role of HE4 in differentiating benign and malignant endometrial pathology.
Gąsiorowska E; Magnowska M; Iżycka N; Warchoł W; Nowak-Markwitz E
Ginekol Pol; 2016; 87(4):260-4. PubMed ID: 27321096
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of ANCCA/ATAD2 in endometrial carcinoma and its correlation with tumor progression and poor prognosis.
Shang P; Meng F; Liu Y; Chen X
Tumour Biol; 2015 Jun; 36(6):4479-85. PubMed ID: 25934333
[TBL] [Abstract][Full Text] [Related]
23. GLUT-1 Expression in Proliferative Endometrium, Endometrial Hyperplasia, Endometrial Adenocarcinoma and the Relationship Between GLUT-1 Expression and Prognostic Parameters in Endometrial Adenocarcinoma.
Canpolat T; Ersöz C; Uğuz A; Vardar MA; Altintaş A
Turk Patoloji Derg; 2016; 32(3):141-7. PubMed ID: 27562387
[TBL] [Abstract][Full Text] [Related]
24. Serum HE4 as a prognostic marker in endometrial cancer--a population based study.
Brennan DJ; Hackethal A; Metcalf AM; Coward J; Ferguson K; Oehler MK; Quinn MA; Janda M; Leung Y; Freemantle M; ; Webb PM; Spurdle AB; Obermair A
Gynecol Oncol; 2014 Jan; 132(1):159-65. PubMed ID: 24211402
[TBL] [Abstract][Full Text] [Related]
25. A critical review on HE4 performance in endometrial cancer: where are we now?
Angioli R; Miranda A; Aloisi A; Montera R; Capriglione S; De Cicco Nardone C; Terranova C; Plotti F
Tumour Biol; 2014 Feb; 35(2):881-7. PubMed ID: 24068567
[TBL] [Abstract][Full Text] [Related]
26. Can Nup88 expression be associated with atypical endometrial hyperplasia and endometrial cancer? A preliminary study.
Li Y; Zhang X; Ge J; Liu X; Xu S; Zhu Z; Fang G; Liu J; Zhang H; Sun X
Pathol Res Pract; 2016 Apr; 212(4):274-8. PubMed ID: 26839161
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of ephrinB2 and EphB4 in tumor advancement of uterine endometrial cancers.
Alam SM; Fujimoto J; Jahan I; Sato E; Tamaya T
Ann Oncol; 2007 Mar; 18(3):485-90. PubMed ID: 17108150
[TBL] [Abstract][Full Text] [Related]
28. Predictive value of serum HE4 and CA125 concentrations for lymphatic metastasis of endometrial cancer.
Wang Y; Han C; Teng F; Bai Z; Tian W; Xue F
Int J Gynaecol Obstet; 2017 Jan; 136(1):58-63. PubMed ID: 28099710
[TBL] [Abstract][Full Text] [Related]
29. Immunolocalization of ERK1/2 and p-AKT in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic significance in malignant group.
Gungorduk K; Ertas IE; Sahbaz A; Ozvural S; Sarica Y; Ozdemir A; Sayhan S; Gokcu M; Yilmaz B; Sanci M; Inan S; Harma M; Yildirim Y
Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():147-52. PubMed ID: 24965996
[TBL] [Abstract][Full Text] [Related]
30. Cyclin D1 is significantly associated with stage of tumor and predicts poor survival in endometrial carcinoma patients.
Khabaz MN; Abdelrahman AS; Butt NS; Al-Maghrabi B; Al-Maghrabi J
Ann Diagn Pathol; 2017 Oct; 30():47-51. PubMed ID: 28965628
[TBL] [Abstract][Full Text] [Related]
31. [Immunomorphologic features of epithelial-stromal relationships at hyperplasia and endometrial carcinoma].
Bantysh BB; Paukov vS; Kogan EA
Arkh Patol; 2012; 74(3):22-5. PubMed ID: 22937575
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of human epididymis protein 4 in endometrial cancer and its utility for surgical staging.
Minar L; Klabenesova I; Jandakova E; Zlamal F; Bienertova-Vasku J
J Obstet Gynaecol Res; 2015 Oct; 41(10):1644-52. PubMed ID: 26223178
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of Musashi-1 in endometrioid adenocarcinoma.
Ma L; Xu YL; Ding WJ; Shao HF; Teng YC
Int J Clin Exp Pathol; 2015; 8(5):4564-72. PubMed ID: 26191146
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of HABP1 correlated with clinicopathological characteristics and unfavorable prognosis in endometrial cancer.
Zhao J; Liu T; Yu G; Wang J
Tumour Biol; 2015 Feb; 36(2):1299-306. PubMed ID: 25355598
[TBL] [Abstract][Full Text] [Related]
35. Further insight into prognostic factors in endometrial cancer: the new serum biomarker HE4.
Capriglione S; Plotti F; Miranda A; Lopez S; Scaletta G; Moncelli M; Luvero D; De Cicco Nardone C; Terranova C; Montera R; Angioli R
Expert Rev Anticancer Ther; 2017 Jan; 17(1):9-18. PubMed ID: 27892774
[TBL] [Abstract][Full Text] [Related]
36. MMP3 in Comparison to CA 125, HE4 and the ROMA Algorithm in Differentiation of Ovarian Tumors.
Cymbaluk-Ploska A; Chudecka-Glaz A; Surowiec A; Pius-Sadowska E; Machalinski B; Menkiszak J
Asian Pac J Cancer Prev; 2016; 17(5):2597-603. PubMed ID: 27268637
[TBL] [Abstract][Full Text] [Related]
37. Importance of Preoperative Knowledge of the Biomarker HE4 in Early-stage Endometrial Cancer Regarding Surgical Management.
Presl J; Ovesna P; Novotny Z; Vlasak P; Bouda J; Kostun J; Topolcan O; Kucera R; Bednarikova M; Weinberger V
Anticancer Res; 2017 May; 37(5):2697-2702. PubMed ID: 28476847
[TBL] [Abstract][Full Text] [Related]
38. Expression profile of eukaryotic translation initiation factor and matrix metalloproteinase 9 in endometrial cancer tissue.
Shi ZM; Liu YN; Fu B; Shen YF; Li LM
J Biol Regul Homeost Agents; 2017; 31(4):1053-1059. PubMed ID: 29254314
[TBL] [Abstract][Full Text] [Related]
39. Maspin expression, subcellular localization and clinicopathological correlation in endometrial hyperplasia and endometrial adenocarcinoma.
Blandamura S; Alessandrini L; Saccardi C; Giacomelli L; Fabris A; Borghero A; Litta P
Histol Histopathol; 2014 Jun; 29(6):777-83. PubMed ID: 24346847
[TBL] [Abstract][Full Text] [Related]
40. [Expression of receptor-binding cancer antigen expressed on SiSo cells in endometrial carcinoma and the correlation thereof with the expression of estrogen receptor subtypes].
Zhou XH; Xu ST; Song WY; Teng XD
Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(27):1900-3. PubMed ID: 17923013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
